Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials.

Fan, Lin; Zhang, Yuanyuan; Maguire, Peter; Muston, Dominic; Monberg, Matthew; Earla, Jagadeswara Rao; Mihai, Adela; Gulati, Poonam

Fan, Lin; Zhang, Yuanyuan; Maguire, Peter; Muston, Dominic; Monberg, Matthew; Earla, Jagadeswara Rao; Mihai, Adela; Gulati, Poonam.

Afiliação

Fan L; Health Economics and Decision Science, Merck & Co., Inc, Rahway, NJ, USA.
Zhang Y; Health Economics and Evidence Generation, Wickenstones Ltd, Milton Park, Oxfordshire, UK.
Maguire P; Health Economics and Evidence Generation, Wickenstones Ltd, Milton Park, Oxfordshire, UK.
Muston D; Health Economics and Decision Science, Merck & Co., Inc, Rahway, NJ, USA.
Monberg M; Center for Observational and Real-World Evidence, Merck & Co., Inc, Rahway, NJ, USA.
Earla JR; Center for Observational and Real-World Evidence, Merck & Co., Inc, Rahway, NJ, USA.
Mihai A; Global Health Economics and Payer Evidence, AstraZeneca PLC, Cambridge, UK.
Gulati P; Global Regulatory Affairs, AstraZeneca PLC, Cambridge, UK.

J Mark Access Health Policy ; 10(1): 2078474, 2022.

Article em En | MEDLINE | ID: mdl-35693379

Palavras-chave

PARP inhibitors; advanced ovarian cancer; adverse event; cost analysis; metastatic breast cancer; platinum-sensitive recurrent ovarian cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: J Mark Access Health Policy Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google